BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 15494350)

  • 1. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
    Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B
    Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines.
    Tamimoto Y; Horiuchi T; Tsukamoto H; Otsuka J; Mitoma H; Kimoto Y; Nakashima H; Muta K; Abe Y; Kiyohara C; Ueda A; Nagasawa K; Yoshizawa S; Shimoda T; Harada M
    Rheumatology (Oxford); 2008 Jun; 47(6):821-7. PubMed ID: 18397955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
    Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
    Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.
    Tokunaga M; Saito K; Kawabata D; Imura Y; Fujii T; Nakayamada S; Tsujimura S; Nawata M; Iwata S; Azuma T; Mimori T; Tanaka Y
    Ann Rheum Dis; 2007 Apr; 66(4):470-5. PubMed ID: 17107983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Fujimoto K; Yamamoto S; Endo T; Sakai T; Obara M; Kumano K; Yamaguchi K; Takeda Y; Goto H; Sato N; Koizumi K; Mukai M; Koike T
    Br J Haematol; 2007 May; 137(4):349-54. PubMed ID: 17456057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
    Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
    Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
    Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
    Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A; White AJ
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE.
    Abdwani R; Mani R
    Lupus; 2009 Apr; 18(5):460-4. PubMed ID: 19318402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA; Kwan-Morley J; Dunham J; Du YZ; Kamoun M; Albert D; Eisenberg RA; Luning Prak ET
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
    Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
    Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.